Evidence map›Paper›PMID 41766356›Full record

ArticleAsia-Pacific journal of clinical oncology2026

Management of Advanced Prostate Cancer in the Asia-Pacific Region: Summary of the Asia-Pacific Advanced Prostate Cancer Symposium 2025.

Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae-Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran and 19 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Edmund ChiongDepartment of Urology, National University Hospital, Singapore, Singapore.
Renu EapenDivision of Cancer Surgery, Department of Genitourinary Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Nicholas BuchanDepartment of Urology, Christchurch Public Hospital, Christchurch, New Zealand.
Kenneth ChenDepartment of Urology, Singapore General Hospital, Singapore, Singapore.
Lukman HakimDepartment of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Agus Rizal HamidDepartment of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Jae-Young JoungDepartment of Urology, Center for Urological Cancer, National Cancer Center, Goyang, South Korea.
Ravindran KanesvaranDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Makarand KhochikarDepartment of Urology/Uro-oncology, Ushakal Abhinav Institute of Medical Sciences, Sangli, India.
Jason LetranDepartment of Urology, Chinese General Hospital and Medical Center, Manila, Philippines.
Bannakij LojanapiwatDepartment of Surgery, Chiang Mai University, Chiang Mai, Thailand.
Indranil MallickDepartment of Radiation Oncology, Tata Medical Center, Kolkata, India.
Chi Fai NgSH Ho Urology Centre, The Chinese University of Hong Kong, Ma Liu Shu, Hong Kong.
Pei Ing NgamDepartment of Diagnostic Imaging, National University Hospital, Singapore, Singapore.
Teng Aik OngDepartment of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Jacob PangDepartment of Urology, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan.
Darren M C PoonDepartment of Clinical Oncology, The Chinese University of Hong Kong, Ma Liu Shu, Hong Kong.
Natasha RobertsSTARS Education and Research Alliance, Metro North Health and The University of Queensland, Herston, Queensland, Australia.
Marniza SaadDepartment of Clinical Oncology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Shinichi SakamotoDepartment of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
Jeremy TeyDepartment of Radiation Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Sue Ping ThangDepartment of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, Singapore.
Poh Choo TohDepartment of Urology, National University Hospital, and Department of Surgery, National University of Singapore, Singapore, Singapore.
Levent TürkeriDepartment of Urology, Altunizade Hospital, Acibadem M.A. Aydinlar University, Istanbul, Türkiye.
Nguyễn Tuấn VinhDepartment of Urology, Binh Dan Hospital, Ho Chi Minh City, Vietnam.
Alvin WongDepartment of Haematology Oncology, National University Hospital, Singapore, Singapore.
Yao ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
ANZUP Cancer Trials GroupLevel 8, Health Translation Hub, Randwick, New South Wales, Australia.
Ian D DavisMonash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-9066-8244

Funding

Australian and New Zealand Urogenital and Prostate Cancer Trials GroupBayerJohnson & JohnsonNHMRC Investigator 2016274NovartisPfizer
6 · The paper itself

Abstract

aimThe aim of the fourth Asia-Pacific Advanced Prostate Cancer Symposium (APAC APCS 2025) was to discuss the application in the Asia-Pacific (APAC) region of outcomes from the fifth Advanced Prostate Cancer Consensus Conference (APCCC 2024).

methodsThe one-day symposium in September 2025 brought together 28 experts from 15 APAC countries or regions. The symposium covered five topics: (1) high-risk localized/locally advanced prostate cancer; (2) prostate-specific antigen persistence and recurrence; (3) radioligand therapy; (4) genetics and genomics; (5) bone protection and other aspects of supportive care. Presymposium polling and expert presentations prefaced in-depth discussions to gather insights on current practice and challenges in the region.

resultsAPAC APCS 2025 highlighted the increasing complexities in diagnosis and management of advanced prostate cancer and the impact on practice of variations in access and cost. Panelists described variations in access and reimbursement for PSMA-PET/CT, abiraterone, androgen receptor pathway inhibitors,

conclusionAPAC Advanced Prostate Cancer Symposia are important forums for discussing APAC-specific considerations in areas where clinical evidence is evolving. In an era of increasingly sophisticated technologies, discussions highlight the importance of not losing sight of patient and clinical factors in decision-making. Multidisciplinary and personalized management is critical, along with the need for locally relevant data to inform APAC-specific guidelines.

Indexed as

Prostatic NeoplasmsAsiaHumansMaleAsia‐Pacificconsensushealth policyprostate cancerrecommendations

Identifiers

PMID41766356
PMCPMC13342456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.